Prices are updated after-hours
Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3    crawled time : 20:00    save search
Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting
Published: 2022-05-02 (Crawled : 20:00) - globenewswire.com
APLS G | $49.08 0.74% 330K twitter stocktwits trandingview |
Health Technology
 | | O: 2.39% H: 4.58% C: -0.87%
phase 3
Fulcrum Therapeutics® Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
Published: 2022-03-03 (Crawled : 20:00) - biospace.com/
FULC | $7.29 -2.02% 110K twitter stocktwits trandingview |
Health Technology
 | | O: -1.71% H: 10.39% C: 7.24%
therapeutics muscular dystrophy trial phase 3
Centessa Pharmaceuticals Doses First Subject in Global Phase 3 ACTION Study of Lixivaptan in Autosomal Dominant Polycystic Kidney Disease
Published: 2022-02-24 (Crawled : 20:00) - biospace.com/
CNTA | News | $8.99 -4.36% 1.4M twitter stocktwits trandingview |
Manufacturing
 | | O: -4.67% H: 9.58% C: 8.44%
als kidney disease phase 3
ObsEva Announces Positive Topline Results for Linzagolix 200 mg with Add-Back Therapy in the Phase 3 EDELWEISS 3 Trial in Patients with Moderate-to-Severe Endometriosis-Associated Pain
Published: 2022-01-06 (Crawled : 20:00) - biospace.com/
OBSV | $0.1018 -15.52% -18.95% 8.2M twitter stocktwits trandingview |
Health Technology
 | | O: 1.94% H: 0.48% C: -4.76%
trial topline results positive therapy linzagolix topline phase 3
MindMed Successfully Completes Phase 1 Clinical Trial of 18-MC
Published: 2022-01-04 (Crawled : 20:00) - biospace.com/
MNMD | $8.44 -4.85% 420K twitter stocktwits trandingview |
n/a
 | | O: -1.32% H: 1.33% C: -1.33%
trial phase 1 phase 2 phase 3
Outlook Therapeutics to Present at the 14th Asia-Pacific Vitreo-Retina Society (APVRS) CongressSuber Huang, MD, MBA, FASRS will present data from the Phase 3 pivotal NORSE TWO registration trial
Published: 2021-12-09 (Crawled : 20:00) - biospace.com/
OTLK | News P | $8.13 -0.85% 150K twitter stocktwits trandingview |
Health Technology
 | | O: 6.0% H: 1.57% C: -6.29%
trial therapeutics retina phase 3
Ionis initiates Phase 3 clinical program of donidalorsen in patients with hereditary angioedema
Published: 2021-11-18 (Crawled : 20:00) - biospace.com/
IONS | $42.1 0.62% 290K twitter stocktwits trandingview |
Health Technology
 | | O: 3.11% H: 0.84% C: -4.03%
ema phase 3 hereditary angioedema
Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals of Oncology
Published: 2021-10-28 (Crawled : 20:00) - prnewswire.com
LLY | News | $731.81 -1.86% 1M twitter stocktwits trandingview |
Health Technology
 | | O: 0.17% H: 1.06% C: 0.39%
ema phase 3 trial
Crinetics Reviews CRN04777 Phase 1 Single-ascending Dose Results
Published: 2021-09-15 (Crawled : 20:00) - crinetics.com
CRNX G | $43.72 -1.13% 100K twitter stocktwits trandingview |
Health Technology
 | | O: -0.47% H: 2.91% C: 0.64%
phase 1 results phase 3 phase 2
Ligand Partner Travere Therapeutics Announces Positive Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Published: 2021-08-16 (Crawled : 20:00) - biospace.com/
TVTX | $5.465 -4.79% 320K twitter stocktwits trandingview |
Health Technology
 | | O: 34.01% H: 3.74% C: -13.37%
SNY | News | $46.615 -2.25% 730K twitter stocktwits trandingview |
Health Technology
 | | O: 0.17% H: 0.62% C: 0.48%
LGND | $70.47 0.83% 41K twitter stocktwits trandingview |
Health Technology
 | | O: -0.76% H: 2.93% C: 1.17%
ongoing positive results topline nephropathy phase 3
Neurocrine Biosciences Announces Completion of Enrollment in Phase 3 KINECT-HD Study Evaluating Valbenazine for Chorea in Huntington Disease
Published: 2021-08-05 (Crawled : 20:00) - prnewswire.com
NBIX | News M | $138.5 -1.14% 350K twitter stocktwits trandingview |
Health Technology
 | | O: -1.31% H: 1.08% C: -2.09%
huntington disease phase 3 enroll huntington’s disease
Vertex to Initiate Phase 3 Development Program for New Once-Daily Triple Combination Regimen in People With Cystic Fibrosis
Published: 2021-07-28 (Crawled : 20:00) - biospace.com/
VRTX | $399.975 -1.22% 360K twitter stocktwits trandingview |
Health Technology
 | | O: 0.0% H: 1.0% C: -0.3%
fibrosis phase 3 cystic fibrosis
OncoSec Enters into a Collaboration Agreement with Merck for a Pivotal Global Phase 3 Study, KEYNOTE-C87, of TAVO™ Combined with KEYTRUDA® for Late-Stage Metastatic Melanoma
Published: 2021-07-06 (Crawled : 20:00) - prnewswire.com
ONCS | $0.2772 25.59% 52M twitter stocktwits trandingview |
Health Services
 | | O: 20.43% H: 26.49% C: 1.19%
collaboration phase 3 keytruda
Upadacitinib (RINVOQ®) Met the Primary and All Secondary Endpoints in the 52-Week Phase 3 Maintenance Study in Ulcerative Colitis Patients
Published: 2021-06-29 (Crawled : 20:00) - biospace.com/
ABBV | News | $168.21 -0.78% 1.2M twitter stocktwits trandingview |
Health Technology
 | | O: -0.31% H: 0.09% C: -0.31%
phase 3 ulcerative colitis
Phase 1, First-in-Human Study of the Probody Therapeutic CX-2029 in Adults with Advanced Solid Tumor Malignancies
Published: 2021-06-10 (Crawled : 20:00) - cytomx.com
CTMX | $1.64 -2.38% 110K twitter stocktwits trandingview |
Health Technology
 | | O: -0.42% H: 1.25% C: -0.42%
phase 1 phase 3 phase 2 solid tumors
Citius Pharmaceuticals Achieves Next Interim Analysis Milestone in its Mino-Lok® Phase 3 Trial
Published: 2021-06-08 (Crawled : 20:00) - biospace.com/
CTXR | $0.7338 -4.37% 390K twitter stocktwits trandingview |
Health Technology
 | | O: 3.92% H: 1.51% C: -3.02%
phase 3 trial milestone
Celyad Oncology to Present Data from Phase 1 IMMUNICY-1 Trial of Non-Gene Edited Allogeneic CAR T Candidate CYAD-211 in Relapsed/Refractory Multiple Myeloma at the European Hematology Association Virtual Congress
Published: 2021-05-12 (Crawled : 20:00) - celyad.com
CYAD | $0.47 -12.49% 49K twitter stocktwits trandingview |
Health Technology
 | | O: 11.11% H: 1.69% C: -2.71%
europe phase 1 trial phase 3 phase 2 car-t
AGTC Reports Positive 12-Month Data from Highest Dose Groups in its Ongoing XLRP Phase 1/2 Clinica
Published: 2021-05-06 (Crawled : 20:00) - agtc.com
AGTC | News | $0.3936 1.23% 0.0% twitter stocktwits trandingview |
Health Technology
 | | O: 1.88% H: 3.24% C: 2.64%
ongoing phase 1 positive phase 3 phase 2
GSI Technology and Partner Space Micro Awarded NASA Phase 1 Contract for Radiation Tolerant AI Processing in Space
Published: 2021-04-06 (Crawled : 20:00) - globenewswire.com
GSIT | $3.72 69K twitter stocktwits trandingview |
Electronic Technology
 | | O: 1.43% H: 7.05% C: 6.79%
phase 1 space contract spac technology phase 3 phase 2
Vuzix Completes Phase 1 Development of a Customized Head Mounted Waveguide-Based Display System for Assisted Medical Cancer Surgeries
Published: 2021-02-04 (Crawled : 20:00) - biospace.com/
VUZI P | $1.295 -1.15% 420K twitter stocktwits trandingview |
Electronic Technology
 | | O: 4.24% H: 4.66% C: 1.31%
cancer phase 1 phase 3 phase 2
Gainers vs Losers
55% 45%

Top 10 Gainers
CZOO | $10.52 110.82% 10M twitter stocktwits trandingview |

CSSE 4 | $0.3181 108.86% 170M twitter stocktwits trandingview |
Consumer Services
BOF | $1.88 60.68% 98M twitter stocktwits trandingview |

AMST | $3.1 55.0% 66M twitter stocktwits trandingview |
Technology Services
LICN | $0.8592 53.43% 13M twitter stocktwits trandingview |

WIMI | $1.03 41.99% 15M twitter stocktwits trandingview |
Technology Services
MULN | News | $3.675 34.62% 11M twitter stocktwits trandingview |
Information
RILY | $28.605 31.7% 9.9M twitter stocktwits trandingview |
Finance
RBBN 4 | $3.305 28.6% 1.9M twitter stocktwits trandingview |
Electronic Technology
RCAT | $1.53 27.5% 2.9M twitter stocktwits trandingview |
Information
Your saved searches
Save your searches and get alerts when important news are released.